PharmTech Drug Digest 11.20
|Articles|September 14, 2016

3M™ Intelligent Control Inhaler

 

3M is proud to provide customers with inhalation, transdermal, oral and topical manufacturing expertise, ensuring the highest standards of manufactured product delivery from feasibility to market. We welcome you to our stand to celebrate 60 years of inhalation firsts and see our latest, the 3M™ Intelligent Control Inhaler. 
A breath of fresh … technology. The 3M™ Intelligent Control Inhaler has the potential to control the spiralling costs of respiratory disease by providing valuable feedback to patients, providers and payers, so they can make informed decisions about treatment. It links to patients' digital devices through a custom app, allowing patients to receive additional support, including the ability to review their usage, set reminders and transmit information to their caregivers. To learn more and find out how you can partner with 3M, visit go. 3M.com/IntelligentControl.

 

Contact Details :
3M
Website: www.3M.com/DDSD


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.